A/H1N1 flu vaccinations will be extended to all risk groups on Monday in Austria, the Austrian Press Agency (APA) said.

According to APA, a total of 1.6 million vaccine doses will be available in Austria until the end of November, and it was estimated this would be sufficient to treat all those at risk. It would be administered through injection at hospitals.

The immunization, with the active agent Celvapan (Baxter), started on Oct. 27 for health care workers.

The Ministry of Health Care said approximately 76,000 pregnant women and 880,000 chronically ill composed Austria's risk group.

Risk persons are people with chronic metabolism disease, cardiovascular disease, chronic liver or kidney's complaint, cancer patients and people suffering from any other immunity debilitating illness. Moreover, diabetes or adiposis patients were especially vulnerable to A/H1N1.

Mothers-to-be and women who plan a pregnancy are also included in the risk group.

The two-part vaccination will be given with a three-week interval. The Austrian health care system will pay for the vaccinations, with the exception of prescription charges.